InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (15 ops.)
Insider track record
CEODisclosed buys
0
Disclosed sells
15
T+90 hit rate
29%
T+90 mean return
-5.6%
Across 7 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the detailed record of transactions filed by KAKKIS EMIL D, Chief Executive Officer. Director active across 1 company, notably Ultragenyx Pharmaceutical Inc.. In total, 25 filings have been recorded. Breakdown: 0 buy · 15 sells. Total volume traded: €11.2m. Activity tracked since 3 May 2021. The latest transaction was filed on 1 March 2025 (Attribution). Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations25 total
43,268 shares0Common StockSEC:0000950170-25-032779:0
11,727 shares@ US$42.233.8% of flowCommon StockSEC:0000950170-24-141485:0
20,000 shares0Common StockSEC:0000950170-24-135521:0
20,000 shares@ US$55.858.1% of flowCommon StockSEC:0000950170-24-103811:0
20,000 shares@ US$50.177.4% of flowCommon StockSEC:0000950170-24-092608:0
38,428 shares0Common StockSEC:0000950170-24-026625:0
30,000 shares@ US$45.0010.1% of flowCommon StockSEC:0001209191-24-002989:0
30,000 shares@ US$47.8710.4% of flowCommon StockSEC:0001209191-24-000071:0
47,853 shares@ US$6.862.5% of flowCommon StockSEC:0001209191-23-053351:0
8,716 shares0Common StockSEC:0001209191-23-016041:0
19,582 shares@ US$45.576.7% of flowCommon StockSEC:0001209191-23-000276:0
12,162 shares@ US$67.370.030% mcap11.5% of flowCommon StockSEC:0001209191-22-015799:0
853 shares@ US$81.000.0024% mcap0.9% of flowCommon StockSEC:0001209191-21-060749:0
853 shares@ US$81.000.5% of flowCommon StockSEC:0001209191-21-060749
852 shares@ US$115.710.0033% mcap1.3% of flowCommon StockSEC:0001209191-21-031383:0
852 shares@ US$115.711.3% of flowCommon StockSEC:0001209191-21-031383
30,000 shares@ US$107.8042.1% of flowCommon StockSEC:0001209191-21-030211
30,000 shares@ US$107.800.11% mcap42.1% of flowCommon StockSEC:0001209191-21-030211:0
2,837 sharesCommon StockSEC:0001562180-16-001158:0
5,465 sharesCommon StockSEC:0001562180-16-001158:1
3,600 sharesCommon StockSEC:0001562180-16-001158:2
2,600 sharesCommon StockSEC:0001562180-16-001158:3
2,191 sharesCommon StockSEC:0001562180-16-001158:4
2,702 sharesCommon StockSEC:0001562180-16-001158:5
605 sharesCommon StockSEC:0001562180-16-001158:6
25 of 25 declarations
About KAKKIS EMIL D
Emil D. Kakkis serves as President and CEO at Ultragenyx Pharmaceutical Inc. In this role, he leads the strategic operations and business management of the company. His expertise in the pharmaceutical sector is essential to guide Ultragenyx towards innovation and growth.
